Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.

ABSTRACT:

Background

Prospectively collected, routine clinical practice-based data on antithrombotic therapy in non-valvular atrial fibrillation (AF) patients are important for assessing real-world comparative outcomes. The objective was to compare the safety and effectiveness of dabigatran versus vitamin K antagonists (VKAs) in patients with newly diagnosed AF.

Methods and results

GLORIA-AF is a large, prospective, global registry program. Consecutive patients with newly diagnosed AF and CHA₂DS₂-VASc scores ≥ 1 were included and followed for 3 years. To control for differences in patient characteristics, the comparative analysis for dabigatran versus VKA was performed on a propensity score (PS)-matched patient set. Missing data were multiply imputed. Proportiona

SUBMITTER: Huisman MV 

PROVIDER: S-EPMC9054866 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature